Enzyme replacement therapy: improving outcomes in rare disease
European Pharmaceutical Review
SEPTEMBER 12, 2024
In 2022, Xenpozyme ® (olipudase alfa) became the first and only approved ASMD therapy. Since the first orphan drug legislation was passed over 40 years ago, the landscape has changed rapidly, and patients are benefiting more and more from breakthrough innovations emerging through this scientific revolution.
52 
Let's personalize your content